Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-09
2011-08-09
Wax, Robert A (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C424S474000, C424S477000
Reexamination Certificate
active
07994226
ABSTRACT:
The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
REFERENCES:
patent: 4324743 (1982-04-01), Feuer
patent: 4959306 (1990-09-01), Kameda et al.
patent: 5639743 (1997-06-01), Kaswan et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 6331316 (2001-12-01), Ullah et al.
patent: 6794414 (2004-09-01), Steinman
patent: 7449451 (2008-11-01), Prasad et al.
patent: 2003/0013642 (2003-01-01), Adamson et al.
patent: 2003/0157191 (2003-08-01), Kil
patent: 2003/0162747 (2003-08-01), Kil
patent: 2004/0033985 (2004-02-01), Chi
patent: 2004/0106591 (2004-06-01), Pacioretty
patent: 2005/0027015 (2005-02-01), Chi et al.
patent: 2005/0137125 (2005-06-01), Chan et al.
patent: 2005/0209441 (2005-09-01), Lile
patent: 2005/0245433 (2005-11-01), Chan
patent: 2006/0140906 (2006-06-01), Chi
patent: 2007/0078113 (2007-04-01), Roth
patent: 2007/0172514 (2007-07-01), Chi
patent: 2009/0023632 (2009-01-01), Adamson et al.
patent: 2009/0076166 (2009-03-01), Dohil et al.
patent: 2004-026716 (2004-01-01), None
patent: 2003/070020 (2003-08-01), None
patent: 2005/049002 (2005-06-01), None
patent: 2005/063226 (2005-07-01), None
patent: 2005/107730 (2005-11-01), None
patent: 2006/072259 (2006-07-01), None
patent: 2007/121545 (2007-11-01), None
patent: 2008/093764 (2008-08-01), None
patent: 2009/070781 (2009-04-01), None
Sokal et al., “Glycogenolytic action of mercaptoethylamine,” Am. J. Physiol., 1959, pp. 261-264, vol. 196, No. 2.
Bacq et al., “The action of cysteamine on liver glycogen,” Arch. Intern. de Physiologie, 1953, pp. 417-418, Vol. LXI, No. 3.
Hanel et al., “The utilization of acetate in rat liver after whole-body roentgen irraditaion,” Int. J. Rad. Biol., 1959, pp. 366-371, vol. 4.
Manowska et al., “Liver and Muscle Glycogen Contents and Blood Glucose Concentration after AET Or MEA Treatment of Adult Male Mice,” Folia Biologica, 1991, pp. 29-31, vol. 31, No. 1-4.
Manowska et al., “Quantiity of Glycogen in the Liver of 19-Day-Old Foetuses After AET, 5-HT, MEA, Or GSH Treatment of Pregnant Mice on the First Day of Gestation,” Acta Physiologica Hungarica, 1988, pp. 51-54, vol. 71, No. 1.
Courrier, “Cortisone Et Sexualite Femelle,” Societe Beige D'Endocrinologie, 1954, pp. 1-5, Annales D'Endocrinologies, T. 15, No. 1.
Fischer, P., “Hepatic glycogen, x-rays, and cysteamine,” 1954, pp. 134-136.
Karnovsky, “Glycogenolytic effect of 2-mercapto-ethylamine in epiphyseal cartilage,” Br J Exp Pathol. Jun. 1961; 42:207-11.
Paoletti et al, “A new hepatic- and irradiation-protective agent, 2-methylpiperazine Dithioformate,” 1960, pp. 688-696.
Van Cauwenberge et al, “Carbohydrate metabolism, adrenal cortex, and sulfur radio-protectors,” 1954, pp. 645-649.
Angulo et al., “Treatment of nonalcoholic fatty liver : present and emerging therapies,” Seminars in Liver Disease, Jan. 1, 2001, pp. 81-88, vol. 21, No. 1.
Castro et al., “Prevention by cystamine of liver necrosis and early biochemical alterations in dicued by carbon tetrachloride,” Biochemical Pharmoacology, Jan. 1, 1972, pp. 49-52, vol. 21, No. 1.
Gulbahar et al., “Treatment of non-alcoholic steatohepatitis with N-acetyl cystein,” Gastroenterology, Apr. 2000, vol. 118, No. 4, Suppl. 2, Part 2.
Marras, G., “Cysteamine and liver disease due to steatogenous diet,” L. Arcispedale S. Anna Di Ferrara, 1955, pp. 639-644, vol. 8, No. 4.
Remmer, H., “Arzneimitteltherapie bei Lebererkrankunge = Drug therapy of liver diseases,” Medizinische Monatsschrift Fuer Pharmazeuten, Jun. 1, 1983, pp. 171-177, vol. 6, No. 6.
Thong-Ngam et al., “N-acetylcystein attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis,” World Journal of Gastroenterology, Oct. 1, 2007, pp. 5127-5132, vol. 13, No. 38.
Madlinska, K., Supplementary European Search Report, EP Appl. No. EP 08 85 3916, Sep. 1, 2010.
Cystagon Summary of Product Characteristics, first approved in 1997 and last updated in 2009.
Cystagon European public assessment report (EPAR), 2004.
Bendel-Stenzel et al., “Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity,” Pediatr Nephrol. Feb. 2008;23(2):311-5. Epub Aug. 1, 2007.
Brok et al., “Intervensions for paracetamol (adetominophen) overdose (Review),” The Cochrane Collaboration, 2009, Issue 1.
Butler et al., “Pantethine and Cystamien Depelete Cystine from Cystinotic Fribroblasts via Efflux of Cysteamine-Cysteine Mixed Disulfide,” J. of Clin. Invest., Aug. 1984, pp. 411-416, vol. 74.
Chang et al., “Therapy of NAFLD; Antioxidants and Cytoprotective Agents,” J. Clin. Gastroenterol., Mar. 2006, pp. S51-S60, vol. 40. Suppl 1.
Dohil et al., “Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease,” Aliment Pharmacol Ther. May 2011;33(9):1036-44. doi: 10.1111/j.0365-2036.2011.04626.x. Epub Mar. 13, 2011.
Dohil et al., “Long-term treatment of cystinosis in children with twice-daily cysteamine,” J Pediatr. May 2010;156 (5):823-7. Epub Feb. 6, 2010.
Dohil et al., “Twice-daily cysteamine bitartrate therapy for children with cystinosis,” J Pediatr. Jan. 2010;156(1):71-75. e1-3. Epub.
Dohil et al., “Understanding intestinal cysteamine bitartrate absorption,” J Pediatr. Jun. 2006;148(6):764-9.
Dohil et al., “Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis,” Pediatr Nephrol. Dec. 2005;20(12):1786-93. Epub Aug. 24, 2005.
Dohil et al., “The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine,” J Pediatr. Aug. 2003;143(2):224-30.
Fidler et al., “Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion,” Br J Clin Pharmacol. Jan. 2007;63(1):36-40.
Gangoiti et al., “Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study,” Br J Clin Pharmacol. Sep. 2010;70(3):376-82.
Kleta et al., “Pharmacological treatmetn of nephropathic cystinosis with cysteamine,” Expert Opin. Pharmacother., 2004, pp. 2255-2262, vol. 5, No. 11.
Kleta, Robert, “A Deeper Look Into Cysteamine Abbsorption for the Treatment of Cystinosis,” J of Pediatrics, 2006, pp. 718-719, vol. 148, No. 6.
Levtchenko et al., “Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis,” Pediatric Nephrol., 2006, pp. 110-113, vol. 21.
Miners et al., “Mechanism of action of paracetomol protective agents in mice in vivo,” Biochemical Pharmacology, 1984, pp. 2995-3000, vol. 33, No. 19.
Shiratori et al., “Evidence for Significant Role of Gastrin in Cysteamine-Induced Hypersecretion of Gastric Acid,” J. of Clin. Gastroenterol., 1997, pp. S84-S88, vol. 25.
Thoene et al., “Cystinosis intracellular cystine depletion by aminothiols in vitro and in vivo,” J. Clinical Investigation, Jul. 1976, pp. 180-189, vol. 58.
van de Berg et al., “Contribution of Gastrin to Cysteamine-induced Gastric Acid Secretion in Rats,” Life Sciences, 1993, pp. 1861-1867, vol. 52, No. 23.
Wang et al., “Cerebral Pet imaging and histological evidence of transglutaminase inhibitor cysteamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease,” J. of the Neurological Sciences, Apr. 2005, pp. 57-66, vol. 231.
http://www.clinicaltrial.gov/ct2/show/NCT00799578, A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis, 2010.
http://www.news-me
Dohil Ranjan
Schneider Jerry
Ahmed Hasan
Baker, Jr. Joseph R.
Gavrilovich Dodd & Lindsey LLP
The Regents of the University of California
Wax Robert A
LandOfFree
Methods of treating non-alcoholic steatohepatitis (NASH)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating non-alcoholic steatohepatitis (NASH)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating non-alcoholic steatohepatitis (NASH)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687234